(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/168011 A1

(51) International Patent Classification:
A61K 31/4178 (2006.01) *A61K 31/415* (2006.01)
A61K 31/445 (2006.01)

(21) International Application Number:
PCT/US2020/018007

(22) International Filing Date:
12 February 2020 (12.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/805,263 13 February 2019 (13.02.2019) US
62/877,232 22 July 2019 (22.07.2019) US

(71) Applicant: **DENALI THERAPEUTICS INC.** [US/US]; 161 Oyster Point Blvd., South San Francisco, California 94080 (US).

(72) Inventors: **CRAIG, Robert, A., II**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **DE VICENTE FIDALGO, Javier**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **ESTRADA, Anthony, A.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **FENG, Jianwen, A.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **FOX, Brian, M.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **OSIPOV, Maksim**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **THOTTUMKARA, Arun**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US).

(74) Agent: **TANNER, Lorna, L.** et al.; Sheppard Mullin Richter & Hampton LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2020/168011 A1

(54) Title: COMPOUNDS, COMPOSITIONS AND METHODS

(57) Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.